Bio-Gene Technology Ltd - Asset Resilience Ratio

Latest as of December 2025: 20.35%

Bio-Gene Technology Ltd (BGT) has an Asset Resilience Ratio of 20.35% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Bio-Gene Technology Ltd carry for a breakdown of total debt and financial obligations.

Liquid Assets

AU$300.00K

≈ $212.27K USD Cash + Short-term Investments

Total Assets

AU$1.47 Million

≈ $1.04 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Bio-Gene Technology Ltd's Asset Resilience Ratio has changed over time. See BGT net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Bio-Gene Technology Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BGT company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$300.00K	20.35%
Total Liquid Assets	AU$300.00K	20.35%

Asset Resilience Insights

Good Liquidity Position: Bio-Gene Technology Ltd maintains a healthy 20.35% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Bio-Gene Technology Ltd Industry Peers by Asset Resilience Ratio

Compare Bio-Gene Technology Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	35.56%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Bio-Gene Technology Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Bio-Gene Technology Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-06-30	23.26%	AU$500.00K ≈ $353.78K	AU$2.15 Million ≈ $1.52 Million	-24.22pp
2024-06-30	47.47%	AU$1.50 Million ≈ $1.06 Million	AU$3.16 Million ≈ $2.24 Million	+46.46pp
2022-06-30	1.02%	AU$74.20K ≈ $52.50K	AU$7.30 Million ≈ $5.17 Million	-77.64pp
2021-06-30	78.65%	AU$3.93 Million ≈ $2.78 Million	AU$5.00 Million ≈ $3.54 Million	-4.82pp
2018-06-30	83.48%	AU$6.40 Million ≈ $4.53 Million	AU$7.67 Million ≈ $5.42 Million	+62.30pp
2017-06-30	21.17%	AU$2.00 Million ≈ $1.42 Million	AU$9.45 Million ≈ $6.68 Million	--

pp = percentage points

About Bio-Gene Technology Ltd

AU:BGT Australia Biotechnology

Market Cap

$8.20 Million

AU$11.59 Million AUD

Market Cap Rank

#27329 Global

#1398 in Australia

Share Price

AU$0.04

Change (1 day)

+2.70%

52-Week Range

AU$0.02 - AU$0.04

All Time High

AU$0.34